Therefore, fatigue isnt that common compared to other side effects and typically goes away on its own
What we do have is a compelling chain of indirect evidence
A reliable AI workflow needs to preserve context: brand versus molecule : Ozempic and Wegovy are both semaglutide, but not the same market object single versus dual agonist : tirzepatide is not simply another semaglutide brand indication : diabetes, obesity, and cardiovascular risk reduction are different analytic frames funding status : PBS and private-pay populations can behave very differently time period : a 2023 shortage-period record is not equivalent to a 2026 post-shortage record source type : TGA, PBS, PBAC, company releases, media reporting, and clinical trials have different evidentiary roles The main AI risk is not that a model cannot summarise GLP-1 information
Mosziski in 1858 (30)
However, individual needs can vary based on factors like personal health, activity level, and specific goals
Dont mix it with other drugs in the same syringe